Metformin + Myoinositol presents as a personalized, multifaceted strategy to better manage PCOS and its associated symptoms, improving the quality of life for patients.
According to research published in the ‘African Journal of Biomedical Research’, Metformin, Myoinositol, and their combination may be highly effective for improving the symptoms of polycystic ovarian syndrome (PCOS). This study by A. Samatha et al. conducted between 2019 and 2021, explored the efficacy and safety of these insulin sensitizers in improving biochemical, clinical, and reproductive parameters in PCOS-affected women.
PCOS is a prevalent hormonal condition that impacts ovarian function, thereby causing menstrual anomalies, infertility and obesity. Diagnosed when a woman has more than 20 follicles in at least 1 ovary, it is often associated with increased levels of androgens, insulin resistance, and other metabolic disturbances.
Conducted across two hospitals in Warangal, India, the study involved 710 women and examined the effects of Metformin, Myoinositol, and a combination of the two. After 6 and 12 months, all treatment groups showed noteworthy improvements in fasting insulin levels, prolactin levels, menstrual complaints and body mass index (BMI). Combination therapy outperformed the individual treatments.
The treatment effects were highly significant (p < .001), with moderate effect sizes confirmed by the statistical analysis. Thus, as insulin sensitizers, Metformin, Myoinositol, and Metformin+Myoinositol contribute to improved biochemical, clinical, and reproductive outcomes in women suffering from PCOS.
African Journal of Biomedical Research
A Study on Insulin Sensitizers in PCOS Using Anonymous Data
A. Samatha et al.
Comments (0)